1. Home
  2. PHAT vs ALT Comparison

PHAT vs ALT Comparison

Compare PHAT & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAT
  • ALT
  • Stock Information
  • Founded
  • PHAT 2018
  • ALT 1997
  • Country
  • PHAT United States
  • ALT United States
  • Employees
  • PHAT N/A
  • ALT N/A
  • Industry
  • PHAT Biotechnology: Pharmaceutical Preparations
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • PHAT Health Care
  • ALT Health Care
  • Exchange
  • PHAT Nasdaq
  • ALT Nasdaq
  • Market Cap
  • PHAT 465.0M
  • ALT 472.3M
  • IPO Year
  • PHAT 2019
  • ALT N/A
  • Fundamental
  • Price
  • PHAT $5.67
  • ALT $6.43
  • Analyst Decision
  • PHAT Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • PHAT 4
  • ALT 7
  • Target Price
  • PHAT $23.00
  • ALT $20.83
  • AVG Volume (30 Days)
  • PHAT 1.0M
  • ALT 2.0M
  • Earning Date
  • PHAT 03-06-2025
  • ALT 02-27-2025
  • Dividend Yield
  • PHAT N/A
  • ALT N/A
  • EPS Growth
  • PHAT N/A
  • ALT N/A
  • EPS
  • PHAT N/A
  • ALT N/A
  • Revenue
  • PHAT $26,270,000.00
  • ALT $52,000.00
  • Revenue This Year
  • PHAT $7,453.23
  • ALT N/A
  • Revenue Next Year
  • PHAT $226.38
  • ALT N/A
  • P/E Ratio
  • PHAT N/A
  • ALT N/A
  • Revenue Growth
  • PHAT N/A
  • ALT N/A
  • 52 Week Low
  • PHAT $5.21
  • ALT $5.28
  • 52 Week High
  • PHAT $19.71
  • ALT $14.84
  • Technical
  • Relative Strength Index (RSI)
  • PHAT 39.59
  • ALT 42.82
  • Support Level
  • PHAT $5.50
  • ALT $6.06
  • Resistance Level
  • PHAT $6.21
  • ALT $7.10
  • Average True Range (ATR)
  • PHAT 0.40
  • ALT 0.36
  • MACD
  • PHAT 0.07
  • ALT 0.03
  • Stochastic Oscillator
  • PHAT 38.69
  • ALT 33.33

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Share on Social Networks: